FDAmanufacturing / CMC66% confidence
CDER’s Framework for Regulatory Advanced Manufacturing Evaluation (FRAME) Initiative
Source: FDA
Why This Matters
Why this matters: provides agency context on manufacturing / CMC that may shape timing or evidence expectations for Accord Biopharma; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Oncology · Supportive Care
- Sub-indication
- General
Related signal: FDA Accepts BLA for ENNUMO (PEGFILGRASTIM-PCCG) by Accord Biopharma